Abstract:
The invention concerns benzoyl derivatives of formula (I) in which the substituents have the following meanings: L and M represent hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C1-C4 alkoxy (these groups being optionally substituted by one to five halogen atoms or C1-C4 alkoxy), halogen, cyano, nitro, a -(Y)n-S(O)mR or -(Y)n-CO-R group; Z represents a five to six-membered heterocyclic saturated or unsaturated group containing one to three heteroatoms selected from the group comprising oxygen, sulphur and nitrogen and which can optionally be substituted by halogen, cyano, nitro, a -CO-R group, C1-C4 alkyl, C1-C4 alkyl halide, C3-C8 cycloalkyl, C1-C4 alkoxy, C1-C4 alkoxy halide, C1-C4 alkyl thio, C1-C4 alkyl thio halide, di-C1-C4 alkyl amino, phenyl optionally substituted by halogen, cyano, nitro, C1-C4 alkyl or C1-C4 alkyl halide, or an oxo group which can be present in the tautomeric form as a hydroxy group, is substituted or, together with a condensation-bound phenyl ring which is optionally substituted by halogen or, cyano, nitro, C1-C4 alkyl or C1-C4 alkyl halide, with a condensation-bound carbocycle or with a condensation-bound second heterocycle which can optionally be substituted by halogen, cyano, nitro, C1-C4 alkyl, di-C1-C4 alkyl amino, C1-C4 alkoxy, C1-C4 alkoxy halide or a C1-C4 alkyl halide, forms a bicyclic system; Y represents O or NR ; n is 0 or 1; m is 0, 1 or 2; R represents C1-C4 alkyl, C1-C4 alkyl halide or NR R ; R represents C1-C4 alkyl, C1-C4 alkyl halide, C1-C4 alkoxy or NR R ; R represents hydrogen or C1-C4 alkyl; R represents C1-C4 alkyl; Q represents a cyclohexane-1,2-dione ring connected at position 2 and of formula (II) in which R , R , R and R represent hydrogen or C1-C4 alkyl, R represents hydrogen, C1-C4 alkyl or a -COOR group, R represents hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, these groups optionally including one to three of the following substituents: halogen, C1-C4 alkyl thio, C1-C4 alkoxy, or R represents tetrahydropropanyl-3, tetrahydropropanyl-4 or tetrahydrothiopyranyl-3, or R and R together form a bond or a three to six-membered carbocyclic ring. The invention also concerns standard agricultural salts of compounds of formula (I) usually utilized in agriculture.
Abstract:
This invention relates to a novel class of sulfonamides that are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting aspartyl protease activity and methods for treating viral infections using the compounds and compositions of this invention.
Abstract:
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin y-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the invention are used as herbicides, pesticides, fungicides, agricultural plant stimulants or antimicrobial agents. The compounds of the present invention can be used for seed treatment. In particular, the compounds of the invention are used as selective herbicides, non-selective herbicides, agricultural herbicides, non-agricultural herbicides or weed killers, herbicides in integrated pest management, herbicides in gardening, herbicides in clearing waste ground, herbicides in clearing industrial or constructions sites, or herbicides in clearing railways and railway embankments.
Abstract:
A compound of formula (I) wherein X is O, C O or S; Y is N or CH; R 2 and R 4 are each independently H, -(CH 2 ) p COOH, -(CH 2 ) p CON(R 5 ) 2 or - (CH 2 ) p COOC 1-6 alkyI; or R 2 and R 4 together form a 6-membered phenyl ring fused to the five membered ring; each R 1 is independently selected from H, halo (e.g. fluoro or chloro), C 6-10 aryl, C 7-12 arylalkyl, C 2-12 alkenyl; OC 1-2 alkyl, OC 2-12 aikenyl or a C 1-12 alkyl group; each R 5 is H or C 1-6 alkyl; each p is 0 to 3; n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof.
Abstract:
A compound of formula (I), useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.
Abstract:
The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Abstract:
The invention relates to compounds of formula (I) wherein A 1 , R 1 , R 2 , R 3 , R 4 and R 5 are defined in the description and in the claims, which are preferential inhibitors of the cysteine protease cathepsin, in particular of the cysteine protease cathepsin S or L, making them useful as medicaments, particularly in the treatment of diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease or diabetic nephropathy.
Abstract:
Compounds of formula (I) are potent and selective antagonists of the 5-HT 2A receptor, and hence are useful in treatment of various CNS disorders.